Anders Osterborg

Summary

Affiliation: Karolinska University Hospital
Country: Sweden

Publications

  1. ncbi request reprint Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study
    Anders Osterborg
    Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
    Br J Haematol 129:206-9. 2005
  2. pmc A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells
    Eva Mikaelsson
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 8:e67601. 2013
  3. ncbi request reprint Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas
    Therese Högfeldt
    Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
    Leuk Lymphoma 55:1158-65. 2014
  4. doi request reprint Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia
    Marzia Palma
    Immune and Gene Therapy Laboratory, Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden
    Exp Hematol 41:615-26. 2013
  5. doi request reprint Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
    Marzia Palma
    Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden
    Cancer Immunol Immunother 61:865-79. 2012
  6. doi request reprint Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
    Amir Hossein Daneshmanesh
    Immune and Gene Therapy Laboratory, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
    Leuk Lymphoma 54:843-50. 2013
  7. doi request reprint Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
    Amir H Daneshmanesh
    Immune and Gene Therapy Lab, CCK, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden
    Int J Cancer 123:1190-5. 2008
  8. doi request reprint Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia
    Anders Osterborg
    Department of Hematology, Karolinska University Hospital Solna, SE 171 76, Stockholm, Sweden
    Curr Hematol Malig Rep 4:47-53. 2009
  9. pmc The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells
    Mohammad Hojjat-Farsangi
    Department of Oncology Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska CCK, Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
    PLoS ONE 8:e78339. 2013
  10. ncbi request reprint Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients
    Amir Osman Abdalla
    Immune and Gene Therapy Laboratory, CCK, Karolinska University Hospital Solna, Stockholm, Sweden
    Eur J Haematol 79:371-81. 2007

Detail Information

Publications48

  1. ncbi request reprint Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study
    Anders Osterborg
    Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
    Br J Haematol 129:206-9. 2005
    ..76). This long-term follow up indicated that epoetin-beta has no significant effect on survival compared to placebo in anaemic patients with lymphoproliferative malignancies...
  2. pmc A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells
    Eva Mikaelsson
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 8:e67601. 2013
    ..The unique expression of a 38 kDa PRELP in CLL cells may suggest involvement in the pathobiology of CLL and merits further studies. ..
  3. ncbi request reprint Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas
    Therese Högfeldt
    Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
    Leuk Lymphoma 55:1158-65. 2014
    ..miR-1234 and STAT3 might be involved in the tumorigenesis of DLBCL of ABC type and possibly associated with environmental background exposure. ..
  4. doi request reprint Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia
    Marzia Palma
    Immune and Gene Therapy Laboratory, Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden
    Exp Hematol 41:615-26. 2013
    ..006 for del-αβ). This study provides a detailed insight into the hTERT transcript pattern in CLL, highlighting the necessity of subgrouping patients according to IGHV mutation status when analyzing hTERT expression...
  5. doi request reprint Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
    Marzia Palma
    Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden
    Cancer Immunol Immunother 61:865-79. 2012
    ..Lack of clinical responses highlights the necessity to develop more potent vaccine strategies in B cell malignancies...
  6. doi request reprint Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
    Amir Hossein Daneshmanesh
    Immune and Gene Therapy Laboratory, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
    Leuk Lymphoma 54:843-50. 2013
    ..05). Thus, a variable staining pattern of ROR1 ranging from very high (CLL, HCL) and high (CML) to intermediate (myeloma and DLBCL) or low (FL) was noted. ROR2 was not detected in hematological malignancies...
  7. doi request reprint Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
    Amir H Daneshmanesh
    Immune and Gene Therapy Lab, CCK, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden
    Int J Cancer 123:1190-5. 2008
    ..The Ror1 protein expression in patients with CLL but not in normal leukocytes merits further studies of its role in the pathobiology of CLL, which may provide a basis for development of Ror1 directed targeted therapy...
  8. doi request reprint Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia
    Anders Osterborg
    Department of Hematology, Karolinska University Hospital Solna, SE 171 76, Stockholm, Sweden
    Curr Hematol Malig Rep 4:47-53. 2009
    ..Results from a range of reports confirm the efficacy of alemtuzumab for the treatment of severe, CLL-related autoimmune cytopenias that have failed to respond to conventional therapies and may even be rituximab-refractory...
  9. pmc The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells
    Mohammad Hojjat-Farsangi
    Department of Oncology Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska CCK, Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
    PLoS ONE 8:e78339. 2013
    ..The mature, phosphorylated ROR1 isoform was associated with a progressive disease stage. Targeting ROR1 by mAbs induced specific dephosphorylation and leukemic cell death. ROR1 might be an interesting therapeutic target. ..
  10. ncbi request reprint Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients
    Amir Osman Abdalla
    Immune and Gene Therapy Laboratory, CCK, Karolinska University Hospital Solna, Stockholm, Sweden
    Eur J Haematol 79:371-81. 2007
    ..To elucidate long-term effects of idiotype (Id) vaccination on Id-specific T cells of multiple myeloma (MM) patients and compare Id-specific T-cell responses of peripheral blood with those of bone marrow (BM)...
  11. doi request reprint Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells
    Aniruddha Choudhury
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Br J Haematol 151:327-35. 2010
    ..This is the first report demonstrating that ROR1 and FMOD may be involved in the survival of CLL cells. ROR1 in particular is further explored as potential target for therapy in CLL...
  12. doi request reprint Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
    Fariba Mozaffari
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
    Cancer Immunol Immunother 58:111-20. 2009
    ..In conclusion, NK-cell cytotoxicity increased during unmaintained long-term follow-up whereas CD4 and regulatory T cells as well as signal transduction molecules remained low following adjuvant radio-chemotherapy...
  13. ncbi request reprint Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy
    Anders Osterborg
    Departments of Oncology and Haematology, Karolinska University Hospital, Stockholm, Sweden
    Br J Haematol 136:736-44. 2007
    ..C.E.R.A. was generally well tolerated in all three groups. C.E.R.A. appeared to have dose-dependent clinical activity in most anaemic patients with aggressive NHL who were receiving chemotherapy...
  14. ncbi request reprint Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia
    Jeanette Lundin
    Departments of Hematology Oncology, Karolinska University Hospital, Stockholm, Sweden
    Semin Hematol 41:234-45. 2004
    ..The availability of an increasing number of new moAbs together with a better understanding of their effector function will hopefully lead to improved therapeutic outcomes for patients with CLL and related disorders...
  15. ncbi request reprint An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma
    Huiqiong Lin
    Department of Oncology Pathology, Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden
    Exp Cell Res 319:600-11. 2013
    ....
  16. doi request reprint Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures
    Therese Högfeldt
    Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
    Leuk Lymphoma 54:996-1003. 2013
    ..The difference in the expression of genes involved in inflammatory responses and in the tumorigenic process of DLBCL might relate to infectious agents and/or other environmental exposures...
  17. doi request reprint Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model
    Pedram Kharaziha
    Department of Oncology Pathology, Cancer Centre Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
    Cancer Res 72:5348-62. 2012
    ..Altogether, our data support the use of sorafenib as a novel therapeutic modality against human multiple myeloma, and its efficacy may be potentiated in combination with ABT737...
  18. ncbi request reprint Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies
    Parviz Kokhaei
    Department of Oncology, Karolinska Institutet, Stockholm, Sweden
    Clin Cancer Res 13:3536-44. 2007
    ..This report describes genomic/protein EPO-R expression and in vitro effects of recombinant human EPO (epoetin) in B-cell chronic lymphocytic leukemia (B-CLL), mantle-cell lymphoma (MCL), and multiple myeloma (MM)...
  19. ncbi request reprint Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia
    Anders Osterborg
    Department of Oncology, Karolinska University Hospital, SE 171 76 Stockholm, Sweden
    Eur J Cancer 43:510-9. 2007
    ..Together with diverging results in the literature, these methodological limitations indicate that findings from preclinical studies must not be over-translated in terms of their clinical relevance to patients with cancer...
  20. doi request reprint Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia
    Claes Karlsson
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Br J Haematol 144:78-85. 2009
    ..Optimized alemtuzumab therapy in properly selected patients may result in high efficacy even in advanced CLL. Our results need to be confirmed in extended studies...
  21. ncbi request reprint New erythropoietic proteins: rationale and clinical data
    Anders Osterborg
    Department of Oncology, Karolinska Institute and Hospital, Stockholm, Sweden
    Semin Oncol 31:12-8. 2004
    ..This review focuses on the available clinical experience with such agents and discusses how dose- and schedule-finding studies are optimizing their clinical use to maximize patient benefits...
  22. doi request reprint Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group
    Eva Kimby
    Karolinska University Hospital, Stockholm, Sweden
    Leuk Lymphoma 49:102-12. 2008
    ....
  23. doi request reprint Ofatumumab, a human anti-CD20 monoclonal antibody
    Anders Osterborg
    Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden
    Expert Opin Biol Ther 10:439-49. 2010
    ..Since relapse of chronic lymphocytic leukemia (CLL), and refractoriness to treatment following relapse, is inevitable after initial treatment, development of novel treatment strategies is necessary...
  24. ncbi request reprint Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
    Jeanette Lundin
    Department of Hematology Oncology, Karolinska Hospital, Stockholm, Sweden
    Blood 101:4267-72. 2003
    ..Alemtuzumab shows promising clinical activity and an acceptable safety profile in patients with advanced MF/SS, particularly in patients with erythroderma and severe itching and those who were not heavily pretreated...
  25. ncbi request reprint Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia
    Mohammad Reza Rezvany
    Immune and Gene Therapy Laboratory, Department of Oncology and Pathology, Cancer Centre Karolinska CCK, Karolinska Institutet, Stockholm, Sweden
    Br J Haematol 135:475-85. 2006
    ..These results indicate that perturbations in the T-cell alterations following alemtuzumab are complex and include not only changes in CD4/CD8 T-cell numbers but also a highly restricted T-cell repertoire especially in CD4 T cells...
  26. ncbi request reprint Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia
    Anders Osterborg
    Karolinska Hospital, Department of Hematology and Oncology, Stockholm, Sweden
    Med Oncol 19:S21-6. 2002
    ..Alemtuzumab treatment has also allowed patients with advanced disease to proceed to stem cell transplantation, and preliminary data indicate that alemtuzumab is highly effective in previously untreated patients with B-CLL...
  27. ncbi request reprint Strategies in the management of alemtuzumab-related side effects
    Anders Osterborg
    Department of Oncology and Hematology, Karolinska University Hospital, Stockholm, Sweden
    Semin Oncol 33:S29-35. 2006
    ..The overall safety profile of alemtuzumab appears to be beneficial in relation to disease severity and prognosis in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia...
  28. ncbi request reprint Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment
    Shahryar Kiaii
    Immune and Gene Therapy Laboratory, Cancer Center Karolinska, Stockholm, Sweden
    Leuk Lymphoma 47:1229-38. 2006
    ..The results suggest that, despite some alterations in signaling molecules and a reduction in T-cell number, overall T-cell functions may be relatively well preserved long-term after treatment with fludarabine and alemtuzumab...
  29. ncbi request reprint Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
    Jeanette Lundin
    Department of Hematology, Karolinska Hospital, and Huddinge University Hospital, Stockholm, Sweden
    Blood 100:768-73. 2002
    ..Prolonged treatment is important for maximal bone marrow response. Subcutaneous administration induced very few "first-dose" flulike symptoms and may reduce health care costs in comparison with the intravenous infusions...
  30. ncbi request reprint Immune response, depression and fatigue in relation to support intervention in mammary cancer patients
    Christina Lindemalm
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
    Support Care Cancer 16:57-65. 2008
    ..To study the effect of support intervention on immune function in breast cancer patients...
  31. ncbi request reprint Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III
    Jeanette Lundin
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    Hematol J 4:248-52. 2003
    ....
  32. ncbi request reprint High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia
    Alejo A Morales
    Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 113:730-7. 2005
    ..05). We conclude that bfl-1 may be an important regulator of B-CLL apoptosis, which could contribute to disease progression and resistance to chemotherapy, and as such represent a future potential therapeutic target...
  33. ncbi request reprint A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
    Gunilla Enblad
    Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
    Blood 103:2920-4. 2004
    ..Further studies are warranted in younger patients and patients with less advanced disease...
  34. ncbi request reprint Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia
    Nina Cavalli-Björkman
    Department of Hematology and Oncology, Karolinska Hospital, Stockholm, Sweden
    Med Oncol 19:277-80. 2002
    ....
  35. ncbi request reprint Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies
    Michael Hedenus
    Medical Department, Sundsvall Hospital, Sundsvall, Sweden
    Br J Haematol 119:79-86. 2002
    ..Confirmative studies at doses of 2.25 and/or 4.5 microg/kg/week in this population are warranted...
  36. ncbi request reprint Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
    Anders Osterborg
    Cancer 97:3125-6; author reply 3126-7. 2003
  37. ncbi request reprint Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies
    Anders Osterborg
    Department of Oncology Radiumhemmet, Karolinska Hospital, S 17176 Stockholm, Sweden
    J Clin Oncol 20:2486-94. 2002
    ....
  38. ncbi request reprint Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations
    Jane Ahlqvist-Rastad
    Medical Products Agency, Uppsala 751 03, Sweden
    Med Oncol 24:267-72. 2007
    ..Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks...
  39. ncbi request reprint CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
    ..We aimed to compare CHOP-like chemotherapy and rituximab with CHOP-like chemotherapy alone in these patients...
  40. doi request reprint Erythropoietins should be used according to guidelines
    Matti S Aapro
    Lancet Oncol 9:412-3. 2008
  41. doi request reprint The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model
    Sixten Borg
    The Swedish Institute for Health Economics IHE, Lund, Sweden
    Acta Oncol 47:1009-17. 2008
    ..It is generally accepted that symptomatic anaemia should be corrected. Treatment options include red blood cell transfusion (RBCT), erythropoietin (EPO) administration or a combination of both...
  42. ncbi request reprint No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome
    Jeanette Lundin
    Blood 105:4148-9. 2005
  43. ncbi request reprint Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia
    Michael Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 4:220-7. 2004
    ..Because high response rates and few complications are observed in previously untreated patients, the use of alemtuzumab earlier in therapy may provide optimum benefit to patients...
  44. ncbi request reprint Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
    Markus Jensen
    University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
    Invest New Drugs 26:139-49. 2008
    ..Further study of R-etodolac as a possible new maintenance therapy or as a part of combination therapy of B-CLL appears warranted...
  45. ncbi request reprint Anemia in multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Wilhelminenspital, Vienna, Austria
    Clin Adv Hematol Oncol 2:233-41. 2004
    ..Recently, an international expert panel recommended the use of rHuEPO for anemic myeloma patients where other possible causes of anemia have been eliminated...
  46. ncbi request reprint Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
    Geoff Hale
    Therapeutic Antibody Centre, Old Road, Headington, Oxford, OX3 7JT, United Kingdom
    Blood 104:948-55. 2004
    ..Subcutaneous alemtuzumab is more convenient and better tolerated but may be associated with some patients forming anti-alemtuzumab antibodies, particularly those patients who were previously untreated...
  47. ncbi request reprint Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
    Youn H Kim
    Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Blood 109:4655-62. 2007
    ..The treatment was well tolerated with no dose-related toxicity other than the targeted depletion of peripheral T cells. A pivotal study has been initiated based on these findings...
  48. ncbi request reprint Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wihelminenspital, Montleartstrasse 37, A 1171 Vienna, Austria
    Hematol J 3:121-30. 2002
    ..Epoetin treatment should be discontinued if there is no response to the increased dosage, or hemoglobin >14 g/dl. Treatment should resume for patients who exceed 14 g/dl, at a reduced dosage, if their hemoglobin falls below 12 g/dl...